NuvOx Pharma and Jiangsu Nhwa Pharmaceutical Co., Ltd. sign Licensing Agreement for Hemorrhagic Shock and Perioperative Blood Loss

First-wordTucson, AZ, January 6th, 2017 - NuvOx Pharma LLC and Jiangsu Nhwa Pharmaceutical Co., Ltd. (SZSE: 002262) have signed a licensing agreement for the exclusive development and sales of NVX-408 for China for treating hemorrhagic shock and perioperative blood loss. NVX-408 is an oxygen therapeutic that is injected intravenously, flows through the lungs and picks up oxygen, then flows through the blood and passes hypoxic tissue then releases oxygen. Pre-clinical studies show that it can improve survival during severe blood loss. Read More ...